Scotiabank Maintains Sector Outperform on Castle Biosciences, Raises Price Target to $37
Portfolio Pulse from Benzinga Newsdesk
Scotiabank analyst Sung Ji Nam maintains a Sector Outperform rating on Castle Biosciences (NASDAQ:CSTL) and raises the price target from $33 to $37.
March 01, 2024 | 5:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Scotiabank has maintained its Sector Outperform rating on Castle Biosciences and increased the price target from $33 to $37.
The upgrade in price target by a reputable analyst like Sung Ji Nam suggests a positive outlook on Castle Biosciences' stock, likely due to strong company fundamentals or growth prospects. This can lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100